Patient characteristics at time of transplantation
. | Phase of disease . | . | . | . | ||
|---|---|---|---|---|---|---|
. | CR1 . | CR2/3 . | Relapse . | Total . | ||
| Total no. of patients | 17 | 7 | 16 | 40 | ||
| Patient age, mo, median (range) | 14.1 (7.3-18.2) | 18.9 (9.3-62.9) | 15.9 (6.1-67.1) | 14.9 (6.1-67.1) | ||
| Time from diagnosis to transplantation, mo, median (range) | 5.6 (2.7-8.1) | 10.3 (5.2-51.1) | 9.2 (5.0-58.9) | 7.1 (2.7-58.9) | ||
| Type of donor, no. patients | ||||||
| Matched sibling | 4 | 2 | 2 | 8 | ||
| Mismatched relative | 4 | 3 | 9 | 16 | ||
| Matched unrelated | 7 | 2 | 5 | 14 | ||
| Mismatched unrelated | 2* | 0 | 0 | 2* | ||
| CMV status, no. patients | ||||||
| + Recipient/+ donor | 1 | 1 | 4 | 6 | ||
| + Recipient/- donor | 3 | 2 | 3 | 8 | ||
| - Recipient/+ donor | 5 | 2 | 0 | 7 | ||
| - Recipient/- donor | 8 | 2 | 8 | 18 | ||
| Not done | 0 | 0 | 1 | 1 | ||
| Source of stem cells, no. patients | ||||||
| BM | 14 | 7 | 16 | 37 | ||
| PBSC | 1 | 0 | 0 | 1 | ||
| UCB | 2 | 0 | 0 | 2 | ||
| Cell count, × 108 TNC/kg, median (range) | 5.0 (0.3-22.0) | 5.7 (4.3-11.9) | 6.8 (3.1-12.9) | 6.4 (0.3-22.0) | ||
| Conditioning regimen, no. patients | ||||||
| CY/ara-C + 12.0 Gy TBI | 2 | 0 | 1 | 3 | ||
| CY + 13.5-13.4 Gy TBI | 13 | 5 | 5 | 23 | ||
| CY + 15.75 Gy TBI | 2 | 1 | 10 | 13 | ||
| BUCY | 0 | 1 | 0 | 1 | ||
| GVHD prophylaxis, no. patients | ||||||
| MTX or CSP only | 2 | 1 | 3 | 6 | ||
| CSP + prednisone | 1 | 0 | 0 | 1 | ||
| MTX + CSP | 14 | 6 | 13 | 33 | ||
| Engraftment, d after HSCT, median (range) | 17 (8-31) | 17 (12-31) | 22 (15-31) | 18 (8-31) | ||
| GVHD, no. evaluable | ||||||
| Acute | 17 | 7 | 15 | 39 | ||
| Stage 0-1 | 6 | 4 | 7 | 17 | ||
| Stage 2-3 | 11 | 3 | 8 | 22 | ||
| Chronic/clinical extensive | 15/4 | 6/1 | 8/2 | 29/7 | ||
| Nonrelapse deaths, no. | ||||||
| VOD | 0 | 1 | 2 | 3 | ||
| Pulmonary hemorrhage | 1 | 0 | 1 | 2 | ||
| Viral pneumonia | 1 | 0 | 1 | 2 | ||
| Relapse after HCT, no. patients | 2† | 3‡ | 11 (102)§ | 16 (114)§ | ||
| Event-free survival, % | 76 | 43 | 6 | 43 | ||
. | Phase of disease . | . | . | . | ||
|---|---|---|---|---|---|---|
. | CR1 . | CR2/3 . | Relapse . | Total . | ||
| Total no. of patients | 17 | 7 | 16 | 40 | ||
| Patient age, mo, median (range) | 14.1 (7.3-18.2) | 18.9 (9.3-62.9) | 15.9 (6.1-67.1) | 14.9 (6.1-67.1) | ||
| Time from diagnosis to transplantation, mo, median (range) | 5.6 (2.7-8.1) | 10.3 (5.2-51.1) | 9.2 (5.0-58.9) | 7.1 (2.7-58.9) | ||
| Type of donor, no. patients | ||||||
| Matched sibling | 4 | 2 | 2 | 8 | ||
| Mismatched relative | 4 | 3 | 9 | 16 | ||
| Matched unrelated | 7 | 2 | 5 | 14 | ||
| Mismatched unrelated | 2* | 0 | 0 | 2* | ||
| CMV status, no. patients | ||||||
| + Recipient/+ donor | 1 | 1 | 4 | 6 | ||
| + Recipient/- donor | 3 | 2 | 3 | 8 | ||
| - Recipient/+ donor | 5 | 2 | 0 | 7 | ||
| - Recipient/- donor | 8 | 2 | 8 | 18 | ||
| Not done | 0 | 0 | 1 | 1 | ||
| Source of stem cells, no. patients | ||||||
| BM | 14 | 7 | 16 | 37 | ||
| PBSC | 1 | 0 | 0 | 1 | ||
| UCB | 2 | 0 | 0 | 2 | ||
| Cell count, × 108 TNC/kg, median (range) | 5.0 (0.3-22.0) | 5.7 (4.3-11.9) | 6.8 (3.1-12.9) | 6.4 (0.3-22.0) | ||
| Conditioning regimen, no. patients | ||||||
| CY/ara-C + 12.0 Gy TBI | 2 | 0 | 1 | 3 | ||
| CY + 13.5-13.4 Gy TBI | 13 | 5 | 5 | 23 | ||
| CY + 15.75 Gy TBI | 2 | 1 | 10 | 13 | ||
| BUCY | 0 | 1 | 0 | 1 | ||
| GVHD prophylaxis, no. patients | ||||||
| MTX or CSP only | 2 | 1 | 3 | 6 | ||
| CSP + prednisone | 1 | 0 | 0 | 1 | ||
| MTX + CSP | 14 | 6 | 13 | 33 | ||
| Engraftment, d after HSCT, median (range) | 17 (8-31) | 17 (12-31) | 22 (15-31) | 18 (8-31) | ||
| GVHD, no. evaluable | ||||||
| Acute | 17 | 7 | 15 | 39 | ||
| Stage 0-1 | 6 | 4 | 7 | 17 | ||
| Stage 2-3 | 11 | 3 | 8 | 22 | ||
| Chronic/clinical extensive | 15/4 | 6/1 | 8/2 | 29/7 | ||
| Nonrelapse deaths, no. | ||||||
| VOD | 0 | 1 | 2 | 3 | ||
| Pulmonary hemorrhage | 1 | 0 | 1 | 2 | ||
| Viral pneumonia | 1 | 0 | 1 | 2 | ||
| Relapse after HCT, no. patients | 2† | 3‡ | 11 (102)§ | 16 (114)§ | ||
| Event-free survival, % | 76 | 43 | 6 | 43 | ||
PBSC indicates peripheral blood stem cell; UCB, umbilical cord blood; TNC, total neutrophil count; ara-C, cytosine arabinoside; BU, busulfan; HSCT, hematopoietic stem cell transplant; VOD, veno-occlusive disease.
One donation was from unrelated BM and 2 were from unrelated cord blood
Time from HCT to relapse was 91 and 188 days, respectively
Time from HCT to relapse was 109, 118, and 746 days, respectively
Parenthetical values indicate the median number of days from HCT to relapse